Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.

Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies

Open access
Zimna, Agnieszka, Kurpisz, Maciej · 2015 · BioMed Research International

Abstract

The cardiovascular system ensures the delivery of oxygen and nutrients to all cells, tissues, and organs. Under extended exposure to reduced oxygen levels, cells are able to survive through the transcriptional activation of a series of genes that participate in angiogenesis, glucose metabolism, and cell proliferation. The oxygen-sensitive transcriptional activator HIF-1 (hypoxia-inducible factor-1) is a key transcriptional mediator of the response to hypoxic conditions. The HIF-1 pathway was found to be a master regulator of angiogenesis. Whether the process is physiological or pathological, HIF-1 seems to participate in vasculature formation by synergistic correlations with other proangiogenic factors such as VEGF (vascular endothelial growth factor), PlGF (placental growth factor), or angiopoietins. Considering the important contributions of HIF-1 in angiogenesis and vasculogenesis, it should be considered a promising target for treating ischaemic diseases or cancer. In this review, we discuss the roles of HIF-1 in both physiological/pathophysiological angiogenesis and potential strategies for clinical therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2015/549412

Cites

139 of 139 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic representation of HIF-α gene structures and DNA binding. (a) HIF-1α and HIF-2α contain the following domains: a nuclear localisation domain (NLS), DNA binding and dimerisation domains (bHLH/PAS), oxygen-dependent degradation domain (ODDD), and cofactor interaction and transcriptional activity domains (N-TAD/C-TAD). HIF-3α lacks a C-TAD domain. NLS: nuclear localisation signal; bHLH: basic helix-loop-helix domain; PAS: Per-ARNT-Sim motif; ODDD: oxygen-dependent degradation domain; N-TAD: N-terminal transactivation domain; C-TAD: C-terminal transactivation domain. (b) Dimerisation of HIF-1α with HIF-1β under hypoxic conditions results in the formation of the HIF-1 transcription factor, which binds to hypoxia response elements (HREs) and activates the transcription of O2-dependent genes (according to [134]).
Figure 1 Schematic representation of HIF-α gene structures and DNA binding. (a) HIF-1α and HIF-2α contain the following domains: a nuclear localisation domain (NLS), DNA binding and dimerisation domains (bHLH/PAS), oxygen-dependent degradation domain (ODDD), and cofactor interaction and transcriptional activity domains (N-TAD/C-TAD). HIF-3α lacks a C-TAD domain. NLS: nuclear localisation signal; bHLH: basic helix-loop-helix domain; PAS: Per-ARNT-Sim motif; ODDD: oxygen-dependent degradation domain; N-TAD: N-terminal transactivation domain; C-TAD: C-terminal transactivation domain. (b) Dimerisation of HIF-1α with HIF-1β under hypoxic conditions results in the formation of the HIF-1 transcription factor, which binds to hypoxia response elements (HREs) and activates the transcription of O2-dependent genes (according to [134]).CC BY · PubMed Central
Figure 2 HIF-1α under normoxic and hypoxic conditions. In the presence of molecular oxygen, 2-oxoglutarate, and Fe2+, HIF-1α is hydroxylated on proline 402 and 564 residues located within ODDD (O2-dependent degradation domain) by prolyl hydroxylase enzymes (PHDs). Hydroxylation results in the binding of the von Hippel-Lindau (VHL) E3 ligase complex, which ubiquitinates HIF-1α, targeting it to proteasomal degradation. The hydroxylation of the asparagine residue prevents CBP/p300 binding to HIF-1α. Under hypoxic conditions, substrates and coactivators of hydroxylation such as O2, Fe(II), and 2-oxoglutarate become limited, which leads to the attenuation of HIF-1α hydroxylation. HIF-1α accumulates in the cytosol and is subsequently translocated into the nucleus where it dimerises with the HIF-1β subunit. The HIF-1α/β dimer binds to HREs and regulates target gene expression.
Figure 2 HIF-1α under normoxic and hypoxic conditions. In the presence of molecular oxygen, 2-oxoglutarate, and Fe2+, HIF-1α is hydroxylated on proline 402 and 564 residues located within ODDD (O2-dependent degradation domain) by prolyl hydroxylase enzymes (PHDs). Hydroxylation results in the binding of the von Hippel-Lindau (VHL) E3 ligase complex, which ubiquitinates HIF-1α, targeting it to proteasomal degradation. The hydroxylation of the asparagine residue prevents CBP/p300 binding to HIF-1α. Under hypoxic conditions, substrates and coactivators of hydroxylation such as O2, Fe(II), and 2-oxoglutarate become limited, which leads to the attenuation of HIF-1α hydroxylation. HIF-1α accumulates in the cytosol and is subsequently translocated into the nucleus where it dimerises with the HIF-1β subunit. The HIF-1α/β dimer binds to HREs and regulates target gene expression.CC BY · PubMed Central
Figure 3 Different strategies in HIF-1α therapies. Depending on the type of disease and the expected therapeutic effect, different approaches are used in HIF-1 therapies: HIF-1 upregulation (ischaemia) to induce angiogenesis or HIF-1 inhibition to attenuate angiogenesis (cancer). DMOG: dimethyloxalylglycine; DFO: 2-OG analogue (N-oxalylglycine); PR39: macrophage-derived peptide; AdHIF-1α and AdHIF-2α: adenoviral vector; AdCA5: adenovirus encoding a constitutively active form of the HIF-1α; BMDAC: bone marrow-derived angiogenic cells; HIF-1α/VP16: DNA-binding and dimerisation domains of HIF-1α fused with the transactivation domain of herpes simplex virus; K14-HIF-1ΔODD: vector encoding O2-independent HIF-1α under the keratin 14 promoter. Silibinin: nontoxic flavonoid; topotecan: chemotherapeutic agent that is a topoisomerase inhibitor; SAHA and FK228: histone deacetylase inhibitors; acriflavine, bortezomib; amphotericin B: anti-HIF drugs.
Figure 3 Different strategies in HIF-1α therapies. Depending on the type of disease and the expected therapeutic effect, different approaches are used in HIF-1 therapies: HIF-1 upregulation (ischaemia) to induce angiogenesis or HIF-1 inhibition to attenuate angiogenesis (cancer). DMOG: dimethyloxalylglycine; DFO: 2-OG analogue (N-oxalylglycine); PR39: macrophage-derived peptide; AdHIF-1α and AdHIF-2α: adenoviral vector; AdCA5: adenovirus encoding a constitutively active form of the HIF-1α; BMDAC: bone marrow-derived angiogenic cells; HIF-1α/VP16: DNA-binding and dimerisation domains of HIF-1α fused with the transactivation domain of herpes simplex virus; K14-HIF-1ΔODD: vector encoding O2-independent HIF-1α under the keratin 14 promoter. Silibinin: nontoxic flavonoid; topotecan: chemotherapeutic agent that is a topoisomerase inhibitor; SAHA and FK228: histone deacetylase inhibitors; acriflavine, bortezomib; amphotericin B: anti-HIF drugs.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 11

  1. 1998, Journal of Cellular Biochemistry, 30-31, 168
  2. 2005, Science's STKE, 2005
  3. 1998, Gene Expression, 7, 205
  4. 1999, Cancer Research, 59, 3915
  5. 2003, Cancer Research, 63, 1138
  6. 1992, Obstetrics and Gynecology, 80, 283
  7. 2015, Tissue Engineering Part A, 21
  8. 1997, Tumour angiogenesis, 181
  9. 1998, Cancer Research, 58, 1408
  10. 2014, Journal of Physiology and Pharmacology, 65, 193
  11. 2000, Nature Medicine, 61, 49

Cited by

See all 650

Metadata

Authors
Zimna, A., & Kurpisz, M.
Affiliations
Institute of Human Genetics (PL)
Corresponding author
Kurpisz, Maciej
Venue
BioMed Research International
Publisher
Wiley
Published
2015
Volume
2015
Pages
1-13
ISSN
  • 1110-7243 (ISSN-L)
  • 2314-6133
  • 2314-6141
OpenAlex
W1597158509
Cited by
604
References
138
Citations by year
2026: 40 · 2025: 66 · 2024: 88 · 2023: 78 · 2022: 67 · 2021: 79 · 2020: 64 · 2019: 45 · 2018: 22 · 2017: 28 · 2016: 23 · 2015: 3
FWCI
2.45
Type
journal article
Language
en
Open access
Locations
  • BioMed Research International (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Science Centre, Poland (2012/07/N/NZ3/01687, 2014/13/B/NZ3/04646, STRATEGMED1/233624/5/NCBR/2014)
  • National Centre for Research and Development (2012/07/N/NZ3/01687, 2014/13/B/NZ3/04646, STRATEGMED1/233624/5/NCBR/2014)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Keywords
HIF-1, angiogenesis, hypoxia, vascular endothelial growth factor, placental growth factor, angiopoietins, vasculogenesis, ischemic diseases, cancer, oxygen sensing, transcriptional regulation
MeSH terms
Placenta Growth Factor, Hypoxia, Humans, Neovascularization, Pathologic, Pregnancy Proteins, Transcriptional Activation, Cell Hypoxia, Neovascularization, Physiologic, Vascular Endothelial Growth Factor A, Hypoxia-Inducible Factor 1, alpha Subunit

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.